secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2023-10-11T23:59:59+00:00
Accession:  0001193125-23-253882
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest TPST-1120 achieves 30% ORR vs 13.3% control in randomized HCC study; adopts poison pill
--------------------------------------------------------------------------------

- Confirmed ORR 30% for TPST-1120 arm vs 13.3% control; duration of response not reached.
- PFS HR 0.7 (median 7 mo vs 4.27 mo); OS HR 0.59 (median not reached vs 15.1 mo).
- In beta-catenin mutation patients, cORR 43% and DCR 100%; in PD-L1 negative, cORR 27% vs 7% control.
- Adopted limited duration rights plan; triggers at 10% (15% passive); expires Oct 2024 or 2026 if approved.
- 40% of TPST-1120 arm patients remain on treatment vs 16.7% control; safety comparable between arms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000119312523253882/0001193125-23-253882-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000119312523253882/d547808d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-253882

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer